JP2022553927A5 - - Google Patents
Info
- Publication number
- JP2022553927A5 JP2022553927A5 JP2022522361A JP2022522361A JP2022553927A5 JP 2022553927 A5 JP2022553927 A5 JP 2022553927A5 JP 2022522361 A JP2022522361 A JP 2022522361A JP 2022522361 A JP2022522361 A JP 2022522361A JP 2022553927 A5 JP2022553927 A5 JP 2022553927A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- pharmaceutical composition
- ilt
- binds
- nkg2a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962914595P | 2019-10-14 | 2019-10-14 | |
| US62/914,595 | 2019-10-14 | ||
| PCT/EP2020/078792 WO2021074157A1 (en) | 2019-10-14 | 2020-10-13 | Treatment of cancer with ilt-2 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022553927A JP2022553927A (ja) | 2022-12-27 |
| JP2022553927A5 true JP2022553927A5 (https=) | 2023-10-18 |
Family
ID=72944114
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022522361A Withdrawn JP2022553927A (ja) | 2019-10-14 | 2020-10-13 | Ｉｌｔ－２阻害剤での癌の処置 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240294634A1 (https=) |
| EP (1) | EP4045535A1 (https=) |
| JP (1) | JP2022553927A (https=) |
| CN (1) | CN114901689A (https=) |
| WO (1) | WO2021074157A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7284256B2 (ja) | 2019-08-12 | 2023-05-30 | ビオンド バイオロジクス リミテッド | Ｉｌｔ２に対する抗体およびその使用 |
| JP2023537396A (ja) | 2020-08-12 | 2023-08-31 | ビオンド バイオロジクス リミテッド | Ｉｌｔ２に対する抗体およびその使用 |
| WO2024140820A1 (zh) * | 2022-12-28 | 2024-07-04 | 浙江博锐生物制药有限公司 | 抗nkg2a抗体及其用途 |
| WO2024260384A1 (en) * | 2023-06-20 | 2024-12-26 | Elpiscience (Suzhou) Biopharma, Ltd. | Antibodies or antigen-binding fragments binding to lilrb1 and uses thereof |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10329348B2 (en) * | 2014-10-23 | 2019-06-25 | Innate Pharma | Treatment of cancers using anti-NKG2A agents |
| SI3405495T1 (sl) * | 2016-01-21 | 2021-08-31 | Innate Pharma | Nevtralizacija inhibitornih poti v limfocitih |
| CN111867614A (zh) * | 2018-01-18 | 2020-10-30 | 艾达奈特公司 | 抗lilrb抗体及其用途 |
| JP2022516140A (ja) * | 2018-12-26 | 2022-02-24 | インネート・ファルマ | 白血球免疫グロブリン様受容体２中和抗体 |
-
2020
- 2020-10-13 WO PCT/EP2020/078792 patent/WO2021074157A1/en not_active Ceased
- 2020-10-13 CN CN202080069390.1A patent/CN114901689A/zh active Pending
- 2020-10-13 US US17/768,484 patent/US20240294634A1/en not_active Abandoned
- 2020-10-13 JP JP2022522361A patent/JP2022553927A/ja not_active Withdrawn
- 2020-10-13 EP EP20793296.3A patent/EP4045535A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022553927A5 (https=) | ||
| JP2020527144A5 (https=) | ||
| WO2020123691A3 (en) | Chimeric antigen receptors and car-t cells and methods of use | |
| Crombet Ramos et al. | Nimotuzumab for patients with inoperable cancer of the head and neck | |
| West et al. | PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells | |
| Ali et al. | Tumor-derived extracellular vesicles impair CD171-specific CD4+ CAR T cell efficacy | |
| PH12019502484A1 (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
| Greiner et al. | NHS-IL12, a tumor-targeting immunocytokine | |
| JP2018522887A5 (https=) | ||
| JP2018524326A5 (https=) | ||
| Burroughs et al. | Treosulfan-based conditioning and hematopoietic cell transplantation for nonmalignant diseases: a prospective multicenter trial | |
| JP2022159548A5 (https=) | ||
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| Perrot et al. | Impact of post-brentuximab vedotin consolidation on relapsed/refractory CD30+ Hodgkin lymphomas: a large retrospective study on 240 patients enrolled in the French Named-Patient Program | |
| JP2017537972A5 (https=) | ||
| JP2016527286A5 (https=) | ||
| IL268620B2 (en) | Antibodies against LAG3 pharmaceutical formulations containing them, and their uses for cancer treatment | |
| JP2015535691A5 (https=) | ||
| JP2018509163A5 (https=) | ||
| MX2022003249A (es) | Anticuerpos anti receptor del factor de necrosis tumoral 2 (tnfr2) y métodos de uso. | |
| JP2020536109A5 (https=) | ||
| JP2018508483A5 (https=) | ||
| JP2019519215A5 (https=) | ||
| JP2016530889A5 (https=) | ||
| JP2018512170A5 (https=) |